Clinical Trial Update: A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions [Phase 2]

View source ↗

Summary

Phase 2 study evaluating efficacy, drug levels, and safety of luspatercept (ACE-536) for anemia due to IPSS-R very low/low/intermediate risk myelodysplastic syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: UNKNOWN